JPWO2020002611A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020002611A5 JPWO2020002611A5 JP2020572372A JP2020572372A JPWO2020002611A5 JP WO2020002611 A5 JPWO2020002611 A5 JP WO2020002611A5 JP 2020572372 A JP2020572372 A JP 2020572372A JP 2020572372 A JP2020572372 A JP 2020572372A JP WO2020002611 A5 JPWO2020002611 A5 JP WO2020002611A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- halo
- independently selected
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 20
- 239000004471 Glycine Substances 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- -1 R 21 Chemical compound 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 125000000732 arylene group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 125000006589 (C3-C10) heterocycloalkylene group Chemical group 0.000 claims 1
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 208000018191 liver inflammation Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 206010047470 viral myocarditis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180450.1 | 2018-06-28 | ||
| EP18180450 | 2018-06-28 | ||
| PCT/EP2019/067351 WO2020002611A1 (en) | 2018-06-28 | 2019-06-28 | Novel lxr modulators with bicyclic core moiety |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021528451A JP2021528451A (ja) | 2021-10-21 |
| JPWO2020002611A5 true JPWO2020002611A5 (https=) | 2022-06-16 |
| JP2021528451A5 JP2021528451A5 (https=) | 2022-06-16 |
| JP7214086B2 JP7214086B2 (ja) | 2023-01-30 |
Family
ID=62947921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572372A Active JP7214086B2 (ja) | 2018-06-28 | 2019-06-28 | 二環式コア部分を有する新規ｌｘｒモジュレーター |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11618747B2 (https=) |
| EP (1) | EP3814331B9 (https=) |
| JP (1) | JP7214086B2 (https=) |
| KR (1) | KR102678581B1 (https=) |
| CN (1) | CN112689630A (https=) |
| AR (1) | AR117599A1 (https=) |
| AU (1) | AU2019293727B2 (https=) |
| BR (1) | BR112020026405A2 (https=) |
| CA (1) | CA3104956C (https=) |
| CL (1) | CL2020003300A1 (https=) |
| DK (1) | DK3814331T3 (https=) |
| EA (1) | EA202092821A1 (https=) |
| ES (1) | ES2956045T3 (https=) |
| FI (1) | FI3814331T3 (https=) |
| HU (1) | HUE063538T2 (https=) |
| IL (2) | IL310623A (https=) |
| LT (1) | LT3814331T (https=) |
| MX (1) | MX2020014258A (https=) |
| PH (1) | PH12020552269A1 (https=) |
| PL (1) | PL3814331T3 (https=) |
| PT (1) | PT3814331T (https=) |
| PY (1) | PY1950412A (https=) |
| SI (1) | SI3814331T1 (https=) |
| SM (1) | SMT202300334T1 (https=) |
| TW (1) | TWI748194B (https=) |
| UY (1) | UY38283A (https=) |
| WO (1) | WO2020002611A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3796975T1 (sl) | 2018-05-22 | 2024-02-29 | Orsobio, Inc. | Derivati sulfonilaminobenzamida |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| WO2021203014A1 (en) | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) |
| IL296920A (en) * | 2020-04-03 | 2022-12-01 | Vertex Pharma | Indole derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1-antitrypsin deficiency (aatd) |
| EP4611746A1 (en) * | 2022-11-03 | 2025-09-10 | OrsoBio, Inc. | Lxr modulators with bicyclic core moiety for treating dyslipidemias |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308850A (en) | 1991-09-30 | 1994-05-03 | Merck Frosst Canada, Inc. | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| US5290798A (en) | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| JPH06145150A (ja) | 1992-11-09 | 1994-05-24 | Kyowa Hakko Kogyo Co Ltd | イミダゾール誘導体 |
| AU4967797A (en) | 1996-11-19 | 1998-06-10 | Kyowa Hakko Kogyo Co. Ltd. | Benzofuran derivatives |
| DE69728688T2 (de) | 1996-11-19 | 2004-08-19 | Amgen Inc., Thousand Oaks | Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel |
| WO1998057931A2 (en) | 1997-06-19 | 1998-12-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DE69842143D1 (de) | 1997-10-24 | 2011-04-07 | Nissan Chemical Ind Ltd | Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| CA2386750A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| AU2001296193B2 (en) | 2000-10-20 | 2006-04-27 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy |
| EP2298738B1 (en) | 2000-11-02 | 2012-09-19 | Wyeth LLC | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| US6503907B2 (en) * | 2000-11-28 | 2003-01-07 | Hoffmann-La Roche Inc. | Indole and dihydroindole derivatives |
| MXPA03005432A (es) | 2000-12-22 | 2003-09-10 | Wyeth Corp | Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6. |
| EP1487776A4 (en) | 2002-03-27 | 2005-05-25 | Smithkline Beecham Corp | ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF |
| WO2004000831A1 (en) | 2002-06-24 | 2003-12-31 | Schering Corporation | Indole derivatives useful as histamine h3 antagonists |
| ES2228267B1 (es) | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
| GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| AU2005211807C1 (en) | 2004-02-11 | 2009-07-16 | Irm Llc | Compounds and compositions as LXR modulators |
| WO2005085188A2 (en) | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| JP4682192B2 (ja) * | 2004-05-03 | 2011-05-11 | エフ．ホフマン−ラ ロシュ アーゲー | 肝ｘ受容体モジュレータとしてのインドリル誘導体 |
| WO2005113499A1 (ja) * | 2004-05-20 | 2005-12-01 | Sankyo Company, Limited | インドール化合物 |
| JP2008509138A (ja) * | 2004-08-03 | 2008-03-27 | ワイス | 心臓血管疾患の治療に有用なインダゾール類 |
| WO2006050236A2 (en) | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| WO2006109633A1 (ja) * | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| FR2886293B1 (fr) * | 2005-05-30 | 2007-08-24 | Fournier S A Sa Lab | Nouveaux composes de l'indoline |
| TW200745031A (en) * | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
| US20070142369A1 (en) | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
| WO2008003736A1 (en) | 2006-07-06 | 2008-01-10 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| US8507469B2 (en) | 2007-03-23 | 2013-08-13 | Abbott Gmbh & Co. Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| CA2681809C (en) * | 2007-03-30 | 2012-06-05 | F. Hoffmann-La Roche Ag | Imidazolidinone derivatives |
| GB0708141D0 (en) * | 2007-04-26 | 2007-06-06 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| ATE541845T1 (de) | 2007-08-29 | 2012-02-15 | Schering Corp | 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen |
| WO2009032116A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| EP2245936A1 (en) | 2009-04-27 | 2010-11-03 | Bayer CropScience AG | Use of 4-aza indole derivatives for the reduction of mycotoxin contamination |
| BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| US8609653B2 (en) | 2011-07-15 | 2013-12-17 | Glaxosmithkline Llc | Azaindole compounds and methods for treating HIV |
| WO2013028999A1 (en) | 2011-08-24 | 2013-02-28 | The Trustees Of Columbia University In The City Of New York | Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders |
| BR112014015298B1 (pt) | 2011-12-22 | 2021-06-15 | Connexios Life Sciences Pvt. Ltd | Composto derivado de aza-adamantano, composição farmacêutica e uso do composto |
| KR20130142801A (ko) | 2012-06-20 | 2013-12-30 | 안국약품 주식회사 | １１β－ＨＳＤ１ 효소의 억제활성을 갖는 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| US9376420B2 (en) | 2012-10-25 | 2016-06-28 | Yuhan Corporation | 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same |
| WO2014085453A2 (en) | 2012-11-29 | 2014-06-05 | The Scripps Research Institute | Small molecule lxr inverse agonists |
| JP6442475B2 (ja) * | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| EP2990403A1 (en) | 2014-08-29 | 2016-03-02 | Novartis Tiergesundheit AG | Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics |
| JP2018500388A (ja) | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
| TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US10227315B2 (en) | 2016-05-18 | 2019-03-12 | Rutgers, The State University Of New Jersey | Mitochondrial uncouplers for treatment of metabolic diseases and cancer |
| UY37659A (es) * | 2017-04-10 | 2018-10-31 | Phenex Fxr Gmbh | Moduladores del receptor x del hígado (lxr) |
| TWI683808B (zh) * | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
| SI3796975T1 (sl) | 2018-05-22 | 2024-02-29 | Orsobio, Inc. | Derivati sulfonilaminobenzamida |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| WO2020257283A1 (en) | 2019-06-18 | 2020-12-24 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| EP4611746A1 (en) | 2022-11-03 | 2025-09-10 | OrsoBio, Inc. | Lxr modulators with bicyclic core moiety for treating dyslipidemias |
-
2019
- 2019-06-18 TW TW108121075A patent/TWI748194B/zh active
- 2019-06-25 PY PY201901950412A patent/PY1950412A/es unknown
- 2019-06-26 AR ARP190101782A patent/AR117599A1/es not_active Application Discontinuation
- 2019-06-28 US US17/255,821 patent/US11618747B2/en active Active
- 2019-06-28 AU AU2019293727A patent/AU2019293727B2/en active Active
- 2019-06-28 EP EP19735528.2A patent/EP3814331B9/en active Active
- 2019-06-28 FI FIEP19735528.2T patent/FI3814331T3/fi active
- 2019-06-28 DK DK19735528.2T patent/DK3814331T3/da active
- 2019-06-28 IL IL310623A patent/IL310623A/en unknown
- 2019-06-28 IL IL279722A patent/IL279722B2/en unknown
- 2019-06-28 KR KR1020217002985A patent/KR102678581B1/ko active Active
- 2019-06-28 PL PL19735528.2T patent/PL3814331T3/pl unknown
- 2019-06-28 EA EA202092821A patent/EA202092821A1/ru unknown
- 2019-06-28 CN CN201980056685.2A patent/CN112689630A/zh active Pending
- 2019-06-28 JP JP2020572372A patent/JP7214086B2/ja active Active
- 2019-06-28 WO PCT/EP2019/067351 patent/WO2020002611A1/en not_active Ceased
- 2019-06-28 HU HUE19735528A patent/HUE063538T2/hu unknown
- 2019-06-28 SI SI201930562T patent/SI3814331T1/sl unknown
- 2019-06-28 UY UY0001038283A patent/UY38283A/es not_active Application Discontinuation
- 2019-06-28 PT PT197355282T patent/PT3814331T/pt unknown
- 2019-06-28 ES ES19735528T patent/ES2956045T3/es active Active
- 2019-06-28 MX MX2020014258A patent/MX2020014258A/es unknown
- 2019-06-28 LT LTEPPCT/EP2019/067351T patent/LT3814331T/lt unknown
- 2019-06-28 SM SM20230334T patent/SMT202300334T1/it unknown
- 2019-06-28 CA CA3104956A patent/CA3104956C/en active Active
- 2019-06-28 BR BR112020026405-9A patent/BR112020026405A2/pt unknown
-
2020
- 2020-12-18 CL CL2020003300A patent/CL2020003300A1/es unknown
- 2020-12-28 PH PH12020552269A patent/PH12020552269A1/en unknown
-
2023
- 2023-02-09 US US18/166,831 patent/US11970484B2/en active Active
-
2024
- 2024-03-05 US US18/596,586 patent/US12291523B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| JP2021528451A5 (https=) | ||
| JP4044967B2 (ja) | １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 | |
| JP2020528889A5 (https=) | ||
| JP2019536765A (ja) | ステロイド及びそのタンパク質コンジュゲート | |
| JP2010540508A5 (https=) | ||
| CN1049428C (zh) | 短效的二氢吡啶类化合物及其制备方法和用途 | |
| JPWO2020123827A5 (https=) | ||
| JP2010506854A5 (https=) | ||
| CA2102454A1 (fr) | Derives de l'erythromycine, leur procede de preparation, leur application comme medicaments | |
| RU2005114010A (ru) | Производные азаиндола в качестве ингибиторов киназы р38 | |
| JP2006509015A5 (https=) | ||
| JP4553166B2 (ja) | ニコチン酸エステルおよびそれを含む薬剤組成物 | |
| JPWO2020002611A5 (https=) | ||
| WO2024140845A1 (zh) | 一种多臂聚乙二醇-药物偶联物 | |
| JP2911239B2 (ja) | スクアレンエポキシダーゼの抑制剤としてのスクアレンのジ−及びテトラ−フルオロ類似体類 | |
| JPWO2019161174A5 (https=) | ||
| JP2006513232A5 (https=) | ||
| JP2005539014A5 (https=) | ||
| PH12022552129A1 (en) | Novel hydroquinone derivatives | |
| RU2004102398A (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости | |
| JP2006506381A5 (https=) | ||
| JP2008511541A5 (https=) | ||
| JPS6036490A (ja) | 水溶性リフアンピシン誘導体 | |
| HU190722B (en) | Process for producing new carbacycline esters and pharmaceutical compositions containing them |